| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1100692592 |
| P356 | DOI | 10.1186/S12977-018-0397-2 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1186/s12977-018-0397-2 |
| P8608 | Fatcat ID | release_232owud27fcgxf2ie5ej6u5wkq |
| P932 | PMC publication ID | 5789533 |
| P698 | PubMed publication ID | 29378657 |
| P50 | author | Alexander O Pasternak | Q57405505 |
| Ben Berkhout | Q29840155 | ||
| P2860 | cites work | Broad activation of latent HIV-1 in vivo | Q37260309 |
| Prolonged persistence of a novel replication-defective HIV-1 variant in plasma of a patient on suppressive therapy | Q37272747 | ||
| Blocked early-stage latency in the peripheral blood cells of certain individuals infected with human immunodeficiency virus type 1 | Q37292229 | ||
| Analysis of human immunodeficiency virus type 1 transcriptional elongation in resting CD4+ T cells in vivo | Q37348552 | ||
| Dynamics of HIV-1 mRNA expression in patients with long-term nonprogressive HIV-1 infection | Q37371274 | ||
| Cellular microRNA and P bodies modulate host-HIV-1 interactions | Q37391014 | ||
| Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study | Q37413059 | ||
| Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues | Q37587740 | ||
| International AIDS Society global scientific strategy: towards an HIV cure 2016. | Q37661770 | ||
| New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. | Q37695001 | ||
| Characterization of the HIV-1 RNA associated proteome identifies Matrin 3 as a nuclear cofactor of Rev function | Q38257666 | ||
| Reversal of Latency as Part of a Cure for HIV-1. | Q38382980 | ||
| HIV-1 Eradication: Early Trials (and Tribulations). | Q38675631 | ||
| Clonal expansion of genome-intact HIV-1 in functionally polarized Th1 CD4+ T cells | Q38719409 | ||
| Persistent HIV-1 replication during antiretroviral therapy | Q38808266 | ||
| HIV-1 transcriptional activity during frequent longitudinal sampling in aviremic patients on antiretroviral therapy | Q38939957 | ||
| Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial | Q38958099 | ||
| Transcriptional architecture of the mammalian circadian clock | Q39042849 | ||
| HIV Latency: Should We Shock or Lock? | Q39078465 | ||
| Long-term decay of the HIV-1 reservoir in HIV-1-infected children treated with highly active antiretroviral therapy. | Q51941671 | ||
| Persistence of intracellular HIV-1 mRNA correlates with HIV-1-specific immune responses in infected subjects on stable HAART. | Q52017490 | ||
| Reverse transcription using random pentadecamer primers increases yield and quality of resulting cDNA. | Q54600921 | ||
| Attenuated and nonproductive viral transcription in the lymphatic tissue of HIV-1-infected patients receiving potent antiretroviral therapy. | Q54734214 | ||
| HIV: Shock and kill. | Q55056512 | ||
| Persistence of HIV-1 Transcription in Peripheral-Blood Mononuclear Cells in Patients Receiving Potent Antiretroviral Therapy | Q57075703 | ||
| Cellular Viral Rebound after Cessation of Potent Antiretroviral Therapy Predicted by Levels of Multiply Spliced HIV‐1 RNA Encodingnef | Q57226464 | ||
| Ongoing HIV Replication During ART Reconsidered | Q57498730 | ||
| Predictors of Virological Outcome and Safety in Primary HIV Type 1-Infected Patients Initiating Quadruple Antiretroviral Therapy: QUEST GW PROB3005 | Q58291249 | ||
| Activation of HIV gene expression during monocyte differentiation by induction of NF-kB | Q59073190 | ||
| Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection | Q73386724 | ||
| Cell-associated HIV-1-DNA quantitation after highly active antiretroviral therapy-treated primary infection in patients with persistently undetectable plasma HIV-1 RNA | Q73386734 | ||
| Steady increase in cellular HIV-1 load during the asymptomatic phase of untreated infection despite stable plasma viremia | Q84395550 | ||
| Modest nonadherence to antiretroviral therapy promotes residual HIV-1 replication in the absence of virological rebound in plasma | Q84883831 | ||
| Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy | Q22251085 | ||
| Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11 | Q24299226 | ||
| Matrin 3 is a co-factor for HIV-1 Rev in regulating post-transcriptional viral gene expression | Q24315683 | ||
| Functional roles for the TATA promoter and enhancers in basal and Tat-induced expression of the human immunodeficiency virus type 1 long terminal repeat | Q24655684 | ||
| Persistence of viral reservoirs in multiple tissues after antiretroviral therapy suppression in a macaque RT-SHIV model | Q27335485 | ||
| RNA structure modulates splicing efficiency at the human immunodeficiency virus type 1 major splice donor | Q28262840 | ||
| Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy | Q28544949 | ||
| Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV | Q28551642 | ||
| Core circadian protein CLOCK is a positive regulator of NF-κB-mediated transcription | Q28591383 | ||
| Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1 | Q28655602 | ||
| Directly infected resting CD4+T cells can produce HIV Gag without spreading infection in a model of HIV latency | Q28728736 | ||
| Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection | Q28748901 | ||
| An inducible transcription factor activates expression of human immunodeficiency virus in T cells | Q29618434 | ||
| Romidepsin-induced HIV-1 viremia during effective ART contains identical viral sequences with few deleterious mutations | Q30490742 | ||
| Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells | Q33250088 | ||
| Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome | Q33521702 | ||
| Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation. | Q33585386 | ||
| Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy | Q33627137 | ||
| Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS | Q33676630 | ||
| Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy | Q33816010 | ||
| High-throughput Characterization of HIV-1 Reservoir Reactivation Using a Single-Cell-in-Droplet PCR Assay | Q33817708 | ||
| Combined single-cell quantitation of host and SIV genes and proteins ex vivo reveals host-pathogen interactions in individual cells | Q33897996 | ||
| A Novel Single-Cell FISH-Flow Assay Identifies Effector Memory CD4+ T cells as a Major Niche for HIV-1 Transcription in HIV-Infected Patients | Q33911247 | ||
| Transcriptional and posttranscriptional regulation of HIV-1 gene expression | Q34030804 | ||
| Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells | Q34059612 | ||
| Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue | Q34152017 | ||
| No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial | Q34220902 | ||
| Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy | Q34290545 | ||
| Establishment and stability of the latent HIV-1 DNA reservoir. | Q39181055 | ||
| Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial | Q39361321 | ||
| Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape. | Q39362365 | ||
| Analysis of multiple cell reservoirs expressing unspliced HIV-1 gag-pol mRNA in patients on antiretroviral therapy | Q39525582 | ||
| Simultaneous ultrasensitive subpopulation staining/hybridization in situ (SUSHI) in HIV-1 disease monitoring | Q39661037 | ||
| In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection | Q39749215 | ||
| Comparison of droplet digital PCR and seminested real-time PCR for quantification of cell-associated HIV-1 RNA. | Q40166933 | ||
| Single-cell analysis of HIV-1 transcriptional activity reveals expression of proviruses in expanded clones during ART. | Q40239429 | ||
| HIV persistence in tissue macrophages of humanized myeloid-only mice during antiretroviral therapy | Q40240401 | ||
| Comparison of digital PCR platforms and semi-nested qPCR as a tool to determine the size of the HIV reservoir | Q40311527 | ||
| Assays for precise quantification of total (including short) and elongated HIV-1 transcripts. | Q40391119 | ||
| A Combinatorial CRISPR-Cas9 Attack on HIV-1 DNA Extinguishes All Infectious Provirus in Infected T Cell Cultures | Q40410004 | ||
| HIV Reservoir: Finding the Right Needles in a Needlestack. | Q40539090 | ||
| Kinetics of HIV-1 Latency Reversal Quantified on the Single-Cell Level Using a Novel Flow-Based Technique | Q40597173 | ||
| PD-1(+) and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals | Q40653907 | ||
| Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study | Q40668686 | ||
| Residual cell-associated unspliced HIV-1 RNA in peripheral blood of patients on potent antiretroviral therapy represents intracellular transcripts. | Q40706493 | ||
| Residual HIV-RNA levels persist for up to 2.5 years in peripheral blood mononuclear cells of patients on potent antiretroviral therapy | Q40751379 | ||
| A human immunodeficiency virus type 1-infected individual with low viral load harbors a virus variant that exhibits an in vitro RNA dimerization defect | Q40763168 | ||
| Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes | Q40886843 | ||
| Minor Contribution of Chimeric Host-HIV Readthrough Transcripts to the Level of HIV Cell-Associated gag RNA. | Q40913399 | ||
| Histone deacetylase inhibitor romidepsin inhibits de novo HIV-1 infections. | Q41036069 | ||
| Detection of HIV-RNA-positive monocytes in peripheral blood of HIV-positive patients by simultaneous flow cytometric analysis of intracellular HIV RNA and cellular immunophenotype | Q41048393 | ||
| Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. | Q41880147 | ||
| Defining total-body AIDS-virus burden with implications for curative strategies | Q41926815 | ||
| The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time | Q41954397 | ||
| The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events. | Q42207197 | ||
| In Vivo Suppression of HIV Rebound by Didehydro-Cortistatin A, a "Block-and-Lock" Strategy for HIV-1 Treatment. | Q42381408 | ||
| Determinants of the NF-kappaB response to acute psychosocial stress in humans | Q43496921 | ||
| Comparison of reverse transcriptases in gene expression analysis. | Q45032299 | ||
| HIV-1 pre-mRNA commitment to Rev mediated export through PSF and Matrin 3. | Q45372623 | ||
| Evaluation of distinct blood lymphocyte populations in human immunodeficiency virus type 1-infected subjects in the absence or presence of effective therapy | Q45746363 | ||
| Cell-associated HIV-1 RNA in blood as indicator of virus load in lymph nodes. The Swiss HIV Cohort Study | Q45747964 | ||
| Human immunodeficiency virus type-1 mRNA splicing pattern in infected persons is determined by the proportion of newly infected cells | Q45760510 | ||
| Identification of Genetically Intact HIV-1 Proviruses in Specific CD4+ T Cells from Effectively Treated Participants. | Q46281767 | ||
| Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. | Q46738531 | ||
| Digital PCR as a tool to measure HIV persistence | Q47548213 | ||
| Inducible HIV RNA transcription assays to measure HIV persistence: pros and cons of a compromise | Q47552344 | ||
| Next-generation in situ hybridization approaches to define and quantify HIV and SIV reservoirs in tissue microenvironments | Q47556370 | ||
| Beyond the replication-competent HIV reservoir: transcription and translation-competent reservoirs. | Q48113493 | ||
| Immune and viral correlates of "secondary viral control" after treatment interruption in chronically HIV-1 infected patients | Q34292622 | ||
| Incomplete adherence to antiretroviral therapy is associated with higher levels of residual HIV-1 viremia | Q34324005 | ||
| HIV-1 DNA predicts disease progression and post-treatment virological control | Q34350410 | ||
| Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy | Q34384134 | ||
| Cell-to-Cell Transmission of HIV-1 Is Required to Trigger Pyroptotic Death of Lymphoid-Tissue-Derived CD4 T Cells | Q34491597 | ||
| Methods for applying accurate digital PCR analysis on low copy DNA samples | Q34614779 | ||
| Highly precise measurement of HIV DNA by droplet digital PCR. | Q34661612 | ||
| Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes | Q34695803 | ||
| Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study | Q34713877 | ||
| Cell-associated viral burden provides evidence of ongoing viral replication in aviremic HIV-2-infected patients | Q34742090 | ||
| Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals | Q34762506 | ||
| A mechanism converting psychosocial stress into mononuclear cell activation | Q34762549 | ||
| Single cell analysis of lymph node tissue from HIV-1 infected patients reveals that the majority of CD4+ T-cells contain one HIV-1 DNA molecule | Q34789289 | ||
| Gag-positive reservoir cells are susceptible to HIV-specific cytotoxic T lymphocyte mediated clearance in vitro and can be detected in vivo [corrected] | Q34950830 | ||
| Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiretro | Q34992440 | ||
| Evaluation of digital PCR for absolute RNA quantification | Q35000858 | ||
| Lack of compartmentalization of HIV-1 quasispecies between the gut and peripheral blood compartments | Q35043695 | ||
| B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers | Q35058635 | ||
| Analysis of multiply spliced transcripts in lymphoid tissue reservoirs of rhesus macaques infected with RT-SHIV during HAART | Q35088292 | ||
| Dynamics of HIV latency and reactivation in a primary CD4+ T cell model | Q35176166 | ||
| Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations | Q35521811 | ||
| Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells | Q35549754 | ||
| HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission | Q35680431 | ||
| Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. | Q35720063 | ||
| The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo | Q35778783 | ||
| Modeling the Effects of Vorinostat In Vivo Reveals both Transient and Delayed HIV Transcriptional Activation and Minimal Killing of Latently Infected Cells | Q35819184 | ||
| The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency | Q35829282 | ||
| Human immunodeficiency virus type 1 cellular RNA load and splicing patterns predict disease progression in a longitudinally studied cohort. | Q35835327 | ||
| Changes in the viral mRNA expression pattern correlate with a rapid rate of CD4+ T-cell number decline in human immunodeficiency virus type 1-infected individuals | Q35837198 | ||
| Dynamics and modulation of human immunodeficiency virus type 1 transcripts in vitro and in vivo | Q35871860 | ||
| The need for treatment interruption studies and biomarker identification in the search for an HIV cure. | Q35928987 | ||
| Early Antiretroviral Therapy in South African Children Reduces HIV-1-Infected Cells and Cell-Associated HIV-1 RNA in Blood Mononuclear Cells. | Q35974409 | ||
| A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals | Q36038655 | ||
| Gene activity in primary T cells infected with HIV89.6: intron retention and induction of genomic repeats. | Q36071452 | ||
| Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes | Q36098975 | ||
| Single-Cell Characterization of Viral Translation-Competent Reservoirs in HIV-Infected Individuals | Q36108518 | ||
| Ex vivo activation of CD4+ T-cells from donors on suppressive ART can lead to sustained production of infectious HIV-1 from a subset of infected cells | Q36287580 | ||
| Cell-Associated HIV-1 DNA and RNA Decay Dynamics During Early Combination Antiretroviral Therapy in HIV-1-Infected Infants. | Q36311438 | ||
| Impact of a decade of successful antiretroviral therapy initiated at HIV-1 seroconversion on blood and rectal reservoirs. | Q36311695 | ||
| Dynamic regulation of HIV-1 mRNA populations analyzed by single-molecule enrichment and long-read sequencing. | Q36368754 | ||
| Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. | Q36369965 | ||
| Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy | Q36481572 | ||
| Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production | Q36547664 | ||
| Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. | Q36654112 | ||
| Novel Assays for Measurement of Total Cell-Associated HIV-1 DNA and RNA. | Q36734972 | ||
| A Subset of CD4/CD8 Double-Negative T Cells Expresses HIV Proteins in Patients on Antiretroviral Therapy. | Q36736780 | ||
| HIV reservoirs and latency models. | Q36746403 | ||
| Highly sensitive methods based on seminested real-time reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 unspliced and multiply spliced RNA and proviral DNA. | Q36747544 | ||
| Cell-associated HIV RNA: a dynamic biomarker of viral persistence | Q36798408 | ||
| The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption | Q36824388 | ||
| A novel PCR assay for quantification of HIV-1 RNA. | Q36827196 | ||
| Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression | Q36830303 | ||
| Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells | Q36882465 | ||
| Persistent HIV-1 replication maintains the tissue reservoir during therapy | Q36897321 | ||
| Short Intracellular HIV-1 Transcripts as Biomarkers of Residual Immune Activation in Patients on Antiretroviral Therapy | Q36950847 | ||
| Biphasic decay kinetics suggest progressive slowing in turnover of latently HIV-1 infected cells during antiretroviral therapy | Q37072991 | ||
| Defining HIV and SIV Reservoirs in Lymphoid Tissues. | Q37090999 | ||
| Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy | Q37161557 | ||
| The distribution of HIV DNA and RNA in cell subsets differs in gut and blood of HIV-positive patients on ART: implications for viral persistence | Q37187497 | ||
| Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size | Q37187501 | ||
| Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation | Q37216773 | ||
| Defective proviruses rapidly accumulate during acute HIV-1 infection | Q37239064 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | T helper cell | Q632518 |
| virus latency | Q4115619 | ||
| human immunodeficiency virus infectious disease | Q18556697 | ||
| HIV type 1 | Q18907320 | ||
| viral RNA | Q27108123 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 13 | |
| P577 | publication date | 2018-01-29 | |
| P1433 | published in | Retrovirology | Q15793508 |
| P1476 | title | What do we measure when we measure cell-associated HIV RNA | |
| P478 | volume | 15 |
| Q48113493 | Beyond the replication-competent HIV reservoir: transcription and translation-competent reservoirs. |
| Q89787445 | CD32+CD4+ T Cells Are Highly Enriched for HIV DNA and Can Support Transcriptional Latency |
| Q89875340 | Cell-associated HIV-1 RNA predicts viral rebound and disease progression after discontinuation of temporary early ART |
| Q63727608 | Characterization of the HIV-1 transcription profile after romidepsin administration in ART-suppressed individuals |
| Q90694289 | Effector memory differentiation increases detection of replication-competent HIV-l in resting CD4+ T cells from virally suppressed individuals |
| Q89685622 | Integrated assessment of viral transcription, antigen presentation, and CD8+ T cell function reveal multiple limitations of class I selective HDACi during HIV-1 latency reversal |
| Q92134571 | Measuring the Success of HIV-1 Cure Strategies |
| Q92538151 | New Frontiers in Measuring and Characterizing the HIV Reservoir |
| Q91947425 | Post-traumatic Stress Disorder, Cocaine Use, and HIV Persistence |
| Q59132651 | Posttranscriptional Regulation of HIV-1 Gene Expression during Replication and Reactivation from Latency by Nuclear Matrix Protein MATR3 |
| Q92146723 | Predictions of time to HIV viral rebound following ART suspension that incorporate personal biomarkers |
| Q52431127 | Tackling HIV Persistence: Pharmacological versus CRISPR-Based Shock Strategies. |
| Q90733079 | The Quest for Cellular Markers of HIV Reservoirs: Any Color You Like |
| Q55514032 | The RNA surveillance proteins UPF1, UPF2 and SMG6 affect HIV-1 reactivation at a post-transcriptional level. |
Search more.